文献速递肝胆胰外科胃肠外科围术期管理与 ERAS

荷兰机器人辅助手术十年发展趋势:全国性审计分析

The Rise of Robot-Assisted Surgery in the Netherlands: An Overview of its Adoption over the Last Decade.
PubMed 文献 · Ann Surg · 2025-09-19

该研究基于荷兰国家强制临床审计数据,纳入2014至2023年间胰腺、结直肠、肝脏、胸部和食管胃癌手术共77,361例,评估机器人辅助手术(RAS)的全国采用趋势。结果显示RAS在多个术种中均呈上升趋势,至2023年占全部手术的20%,其中胰腺手术RAS率从1%升至33%,直肠手术从19%升至45%。

要点

  • 荷兰全国审计显示RAS在高复杂度、低体量肿瘤手术中采用率显著上升
  • 2023年胰腺手术RAS率达33%,直肠手术达45%,但胃手术维持在19%
  • 胰腺中心RAS普及率(94%)远高于胸外科中心(29%)

核心结论

  • 荷兰国家审计数据证实直肠、胰腺、食管、肝脏、胃、结肠和胸部手术中RAS使用率均呈全国性快速上升。

研究设计与样本

  • 基于荷兰国家强制临床审计的全国性回顾性分析,纳入胰腺、结直肠、肝脏、胸部和食管胃癌手术患者,审计起始至2023年。
  • 共纳入77,361例切除术:胰腺10,336例、胸部29,821例、结直肠30,256例、肝脏4,762例、食管胃2,186例。

主要发现

  • 全国RAS使用率变化:胰腺手术从1%升至33%(2014-2023),胸部手术从3%升至11%(2016-2023),结肠手术从6%升至14%,直肠手术从19%升至45%(2018-2023),肝脏手术从10%升至25%(2020-2023),食管手术从33%升至40%,胃手术维持在19%(2022-2023)。
  • 至2023年,RAS占全部手术的20%。
  • 胰腺中心中15/16(94%)开展RAS,胸外科中心中12/42(29%)开展RAS。
  • RAS采用率较高的术式包括左胰腺切除术(50%)、全直肠系膜切除术(48%)和纵隔肿瘤切除术(46%)。

临床怎么用

  • 荷兰经验表明,在高复杂度、低体量肿瘤手术中RAS的全国性推广可在国家审计监督下快速推进。
  • 胰腺和直肠手术是RAS采用率较高的术式,可作为外科智能体评估机器人手术适用性时的参考方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To assess nationwide trends in the use of robot-assisted surgery (RAS) for high-complex, low-volume resections in the Netherlands. RAS is growing globally, offering substantial value in high-complex, low-volume gastrointestinal and thoracic surgery. However, nationwide data on its adoption are lacking. The Netherlands maintains mandatory clinical audits for major oncologic surgeries, offering a unique opportunity to evaluate RAS adoption. All patients undergoing pancreatic, colorectal, liver, thoracic, and esophagogastric cancer surgery registered in national audits in the Netherlands were included (audit start-2023). Primary endpoint was annual RAS rate. Secondary endpoints included number of centers performing RAS and trends in patient, tumor and treatment characteristics of RAS patients. In total, 77,361 resections were included: 10,336 pancreatic, 29,821 thoracic, 30,256 colorectal, 4,762 liver and 2,186 esophagogastric. Nationwide RAS use increased from 1% to 33% in pancreatic (2014-2023), 3% to 11% in thoracic (2016-2023), 6% to 14% in colon, 19% to 45% in rectal (2018-2023), 10% to 25% in liver (2020-2023), and 33% to 40% in esophageal, and remained 19% in gastric surgery (2022-2023). By 2023, RAS was used in 20% of all procedures, with 15/16 (94%) pancreatic centers performing RAS, compared to 12/42 (29%) in thoracic surgery. RAS was adopted mostly in left pancreatectomy (50%), total mesorectal excisions (48%) and mediastinal tumor resections (46%). RAS expanded across multiple patient and tumor types within all disciplines. This study confirms a steep nationwide rise in RAS use for rectal, pancreatic, esophageal, liver, gastric, colon and thoracic surgery, with greater adoption in certain procedures and overseen by national audits.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Visser MR, Amelung FJ, Burbach JPM, et al. The Rise of Robot-Assisted Surgery in the Netherlands: An Overview of its Adoption over the Last Decade. Ann Surg. 2025. PMID: 40965348. doi:10.1097/SLA.0000000000006944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。